NCT03703310 2024-07-03Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)Sol-Gel Technologies, Ltd.Phase 3 Completed174 enrolled 23 charts